Article Text

Download PDFPDF
Randomised controlled trial
Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors KMD and KS contributed equally to writing and revising this manuscript.

  • Competing interests KMD serves as site primary investigator for multicenter trials sponsored by Sanofi, GSK, Grifols, Merck, Astra Zeneca and Regeneron and as primary investigator for investigator initiated trial funded by Merck. KMD is involved in advising activities for Eli Lilly and consulting activities for GSK. KS serves as site primary investigator for multicenter trials sponsored by Eli Lilly.

  • Provenance and peer review Commissioned; internally peer reviewed.